GYL Financial Synergies LLC Decreases Holdings in Eli Lilly And Co (NYSE:LLY)

GYL Financial Synergies LLC lessened its stake in shares of Eli Lilly And Co (NYSE:LLY) by 19.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,787 shares of the company’s stock after selling 432 shares during the period. GYL Financial Synergies LLC’s holdings in Eli Lilly And Co were worth $235,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. BlackRock Inc. grew its position in Eli Lilly And Co by 1.5% in the second quarter. BlackRock Inc. now owns 61,979,145 shares of the company’s stock valued at $6,866,670,000 after acquiring an additional 898,845 shares during the last quarter. Patten & Patten Inc. TN raised its holdings in shares of Eli Lilly And Co by 6.7% during the third quarter. Patten & Patten Inc. TN now owns 5,590 shares of the company’s stock valued at $625,000 after purchasing an additional 351 shares during the period. Exane Derivatives boosted its position in shares of Eli Lilly And Co by 561.6% during the 3rd quarter. Exane Derivatives now owns 6,537 shares of the company’s stock worth $731,000 after purchasing an additional 5,549 shares in the last quarter. First Financial Corp IN boosted its position in shares of Eli Lilly And Co by 1.8% during the 3rd quarter. First Financial Corp IN now owns 9,536 shares of the company’s stock worth $1,066,000 after purchasing an additional 169 shares in the last quarter. Finally, DNB Asset Management AS increased its position in Eli Lilly And Co by 3.9% in the 3rd quarter. DNB Asset Management AS now owns 234,887 shares of the company’s stock valued at $26,267,000 after buying an additional 8,882 shares in the last quarter. 76.28% of the stock is currently owned by institutional investors and hedge funds.

NYSE:LLY opened at $143.15 on Thursday. Eli Lilly And Co has a 52 week low of $101.36 and a 52 week high of $147.87. The firm has a 50-day moving average price of $138.13 and a two-hundred day moving average price of $119.68. The company has a debt-to-equity ratio of 4.09, a quick ratio of 0.88 and a current ratio of 1.17. The firm has a market cap of $139.71 billion, a price-to-earnings ratio of 16.34, a price-to-earnings-growth ratio of 1.61 and a beta of 0.21.

Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Thursday, January 30th. The company reported $1.73 earnings per share for the quarter, topping analysts’ consensus estimates of $1.52 by $0.21. The firm had revenue of $6.11 billion for the quarter, compared to the consensus estimate of $5.92 billion. Eli Lilly And Co had a return on equity of 188.01% and a net margin of 37.27%. The company’s revenue was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.33 EPS. As a group, sell-side analysts forecast that Eli Lilly And Co will post 6.76 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 14th will be given a dividend of $0.74 per share. The ex-dividend date is Thursday, February 13th. This represents a $2.96 annualized dividend and a yield of 2.07%. This is a positive change from Eli Lilly And Co’s previous quarterly dividend of $0.65. Eli Lilly And Co’s dividend payout ratio is presently 42.72%.

A number of equities analysts have recently weighed in on the company. UBS Group lowered their target price on Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating on the stock in a research report on Thursday, October 17th. Argus upped their price objective on shares of Eli Lilly And Co from $145.00 to $165.00 and gave the stock a “buy” rating in a report on Monday, December 30th. Morgan Stanley raised shares of Eli Lilly And Co from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $116.00 to $150.00 in a research note on Wednesday, December 18th. They noted that the move was a valuation call. JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly And Co from $140.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, December 18th. Finally, Mizuho started coverage on shares of Eli Lilly And Co in a report on Wednesday, February 5th. They set a “neutral” rating and a $148.00 price objective for the company. Six analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Eli Lilly And Co presently has an average rating of “Buy” and an average target price of $137.36.

In other news, SVP Myles O’neill sold 25,000 shares of the stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the completion of the transaction, the senior vice president now directly owns 40,424 shares of the company’s stock, valued at approximately $4,850,880. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 220,000 shares of the stock in a transaction that occurred on Thursday, January 9th. The shares were sold at an average price of $135.79, for a total transaction of $29,873,800.00. Following the transaction, the insider now directly owns 114,136,224 shares of the company’s stock, valued at $15,498,557,856.96. The disclosure for this sale can be found here. Insiders have sold 1,609,483 shares of company stock valued at $206,714,535 in the last 90 days. 0.11% of the stock is currently owned by corporate insiders.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: Why is cost of goods sold important?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.